Therapeutic efficacy of erythropoietin alfa and erythropoietin beta in hemodialysis; a randomized controlled trial

Introduction: anemia, as a common complication of end-stage renal disease (esrd), usuallydevelops due to erythropoietin deficiency. recombinant human erythropoietins (rhepos)are indicated for the correction of renal anemia.objectives: we aimed to evaluate the efficacy of a new brand of erythropoietin namedcinnapoietin (erythropoietin beta) on hemoglobin levels.patients and methods: this is a randomized double-blinded controlled trial. ninety-sixesrd patients on hemodialysis recruited in the study, whose hemoglobin levels was less than10 g/dl. they allocated to two groups. pdpoetin (erythropoietin alfa) 50-100 u/kg threetimes per week intravenously administrated to the control group and cinnapoietin withexactly same regimen as like pdpoetin group administrated for the rest of the participants.the study duration was 3 months. we measured plasma hemoglobin monthly for 3 months.results: we found, hemoglobin was increased across the time and it was statisticallysignificant (p < 0.001), while there was no statistically significant differences between thegroups (p = 0.712).conclusion: according to the result of the present study there is no statistical significantdifference between these two brands of exogenous rhepo in the case of increasing thehemoglobin concentration.